Sun-Hoffman Consulting

 

Lin Sun-Hoffman, Ph.D., J.D.

Dr. Sun-Hoffman primarily consults on biotechnology and pharmaceutical business-related matters. Her clients include U.S. –based drug companies and non-profit professional associations as well as several China-based organizations. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. Specifically her expertise is in developing and maintaining relationships on behalf of her clients with local and regional Chinese government entities as well as China Central government agencies such as the State Food and Drug Administration (SFDA), State Intellectual Property Office (SIPO), General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), the Ministry of Health (MOH), the Ministry of Agriculture (MOA) and the Ministry of Science and Technology (MOST).

Since 2009 Dr. Sun-Hoffman has served as the China Medical City (CMC)’s U.S. representative. CMC aims to become China’s  largest   pharmaceutical, biotechnology, and medical equipment development zone; it provides cutting-edge support services plus streamlined regulatory and registration processes. Dr. Sun-Hoffman also serves as an advisor to the Shanghai Overseas Chinese Affairs Office and to the Sichuan state’s  Overseas Chinese Affairs Office. The U.S. Grocery Manufacturers  Association  (GMA)’s  Chief Advisor for Asia is Dr. Sun- Hoffman’s  most  recent  appointment.

From 2009 to 2011 Dr. Sun-Hoffman was the Chief Advisor for Asia at
the Biotechnology Industry Organization (BIO). During her service at BIO, she successfully raised a substantial amount in sponsorships for BIO and she organized the first BIO conference to be held in China (BioChina conference; Shanghai, October 2011). Dr. Sun-Hoffman was also the principal organizer  of  the  first  “BIO  CEO”  trip to China (March 28-April 1, 2011). The CEO delegation was comprised of members of BIO’s   Executive  Board  members  and  it  was  BIO’s  highest-level visit to China.

Areas of Expertise

Familiar with Chinese regulatory and legal systems in life science, food and consumer products.

Strong connections with Chinese biotechnology and pharmaceutical associations and industry.

Strong government relationship development skills in China, especially in SFDA, SIPO, AQSIQ, MOH, MOST.

Provide Partnership service between US companies and Chinese companies.

10 + years Intellectual Property and transactional legal experience as an in-house patent counsel.